If the physicians detect malignant tumor tissue in the biopsy, they usually have to remove the prostate. However, besides the aggressive form of prostate cancer, there is also a type that only grows very slowly and may not need to be operated on. …
Angiogenesis creates new blood vessels in a process that can lead to the onset and progression of several diseases such as cancer and age-related macular degeneration. Vascular endothelial growth factor (VEGF) is a signaling protein produced by damaged cells, which binds to one of its receptors VEGFR-2, located on the surface of blood vessel cells. …
The researchers also found that anti-cholesterol drugs such as statins appear to diminish the effect of this estrogen-like molecule. …
The results from the Global Opioid Policy Initiative (GOPI) project show that more than 4 billion people live in countries where regulations leave cancer patients suffering excruciating pain. National governments must take urgent action to improve access to these medicines, says the European Society for Medical Oncology, leader of a group of 22 partners that have launched the first global survey to evaluate the availability and accessibility of opioids for cancer pain management. "The GOPI study has uncovered a pandemic of over-regulation in much of the developing world that is making it catastrophically difficult to provide basic medication to relieve strong cancer pain," says Nathan Cherny, Chair of the ESMO Palliative Care Working Group and lead author of the report, from Shaare Zedek Medical Center, Jerusalem, Israel. "Most of the world’s population lacks the necessary access to opioids for cancer pain management and palliative care, as well as acute, post-operative, obstetric and chronic pain." "When one considers that effective treatments are cheap and available, untreated cancer pain and its horrendous consequences for patients and their families is a scandal of global proportions," Cherny says…
Now, researchers from MIT and Brigham and Women’s Hospital (BWH) have developed a new type of nanoparticle that can be delivered orally and absorbed through the digestive tract, allowing patients to simply take a pill instead of receiving injections. In a paper appearing in the Nov. 27 online edition of Science Translational Medicine, the researchers used the particles to demonstrate oral delivery of insulin in mice, but they say the particles could be used to carry any kind of drug that can be encapsulated in a nanoparticle…
Now, researchers from MIT and Brigham and Women’s Hospital (BWH) have developed a new type of nanoparticle that can be delivered orally and absorbed through the digestive tract, allowing patients to simply take a pill instead of receiving injections. In a paper appearing in the Nov. …
"We discovered that the enzyme USP13 stabilizes the PTEN protein by reversing a process that marks various proteins for destruction by the cell’s proteasome," said the paper’s senior author Li Ma, Ph.D., assistant professor of Experimental Radiation Oncology. "USP13 also suppresses tumor formation and glycolysis though PTEN," Ma said. Glycolysis is a glucose metabolism pathway that tumors rely on to thrive and grow…
Adult stem cells are tissue-specific regenerative cells that replace diseased or damaged cells in the body’s organs. Drs. Goldstein, Witte and colleagues previously reported in Science that prostate cancer can start in basal type stem cells…
The process includes first writing for oneself in emotionally expressive ways about the trauma of the cancer and transplant experience, followed by peer helping, which includes writing as if speaking to a person ready to undergo the transplant procedure about the survivor’s experience while offering advice and encouragement. …
PNP confirmed that it has completed the first three cohorts of its Phase I clinical trial and is now recruiting for the fourth cohort. The company is looking ahead to Phase II trials and seeking an appropriate partner in the pharmaceutical industry. "We are pleased with the progress made by the product thus far," said William B. Parker, Ph.D., senior research fellow at Southern Research Institute. …